Clinical Report: Evaluating the Relationship Between HALP Scores and Survival Outcomes
Overview
This meta-analysis investigates the prognostic significance of initial HALP scores in patients with esophageal cancer (EC) and gastro-esophageal junction cancer (GEC).
Background
Esophageal cancer and gastro-esophageal junction cancer are among the most aggressive gastrointestinal cancers, with low long-term survival rates despite advancements in treatment. Traditional staging systems often fail to reflect biological variances, prompting the need for reliable prognostic biomarkers. The HALP score, which incorporates hemoglobin, albumin, lymphocyte, and platelet levels, may serve as a valuable tool for predicting patient outcomes.
Data Highlights
Outcome
Hazard Ratio (HR)
95% Confidence Interval (CI)
Overall Survival
1.74
1.53-1.98
Progression-Free Survival
1.82
1.40-2.37
Key Findings
Low HALP scores correlate with inferior overall survival in EC and GEC patients.
Patients with low HALP scores have a hazard ratio of 1.74 for overall survival compared to those with high scores.
Low HALP scores are associated with diminished progression-free survival, with a hazard ratio of 1.82.
The relationship between HALP scores and survival outcomes is consistent across various subgroups.
The analysis included data from ten cohort studies involving 1,953 patients.
Clinical Implications
The HALP score may be a useful prognostic tool for clinicians managing patients with esophageal and gastro-esophageal junction cancers.
Conclusion
Reduced baseline HALP scores are correlated with inferior OS and PFS in EC or GEC patients.
